AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
The Immunotherapy Landscape in Colorectal Cancer: Where We Stand and Where We're Headed
By Ibrahim Halil Sahin, MD
Expert commentary on the evolving role of immunotherapy in colorectal cancer, including MSI-H breakthroughs, MSS challenges, biomarker-driven treatment, and emerging clinical trial strategies.
The Immunotherapy Landscape in Colorectal Cancer: Where We Stand and Where We're Headed
By Ibrahim Halil Sahin, MD
Expert commentary on the evolving role of immunotherapy in colorectal cancer, including MSI-H breakthroughs, MSS challenges, biomarker-driven treatment, and emerging clinical trial strategies.
The Immunotherapy Landscape in Colorectal Cancer: Where We Stand and Where We're Headed
By Ibrahim Halil Sahin, MD
Expert commentary on the evolving role of immunotherapy in colorectal cancer, including MSI-H breakthroughs, MSS challenges, biomarker-driven treatment, and emerging clinical trial strategies.
CAR-T Cell Therapy in Aggressive Lymphoma: Navigating Standard-of-Care Products, Sequencing Strategies, and the Road to Frontline Use
By Elif Yilmaz, MD
Expert commentary on CAR-T cell therapy in aggressive lymphoma, including DLBCL and mantle cell lymphoma, with insights on product selection, toxicity, sequencing strategies, and frontline applications.
CAR-T Cell Therapy in Aggressive Lymphoma: Navigating Standard-of-Care Products, Sequencing Strategies, and the Road to Frontline Use
By Elif Yilmaz, MD
Expert commentary on CAR-T cell therapy in aggressive lymphoma, including DLBCL and mantle cell lymphoma, with insights on product selection, toxicity, sequencing strategies, and frontline applications.
CAR-T Cell Therapy in Aggressive Lymphoma: Navigating Standard-of-Care Products, Sequencing Strategies, and the Road to Frontline Use
By Elif Yilmaz, MD
Expert commentary on CAR-T cell therapy in aggressive lymphoma, including DLBCL and mantle cell lymphoma, with insights on product selection, toxicity, sequencing strategies, and frontline applications.
Building CAR-T Access Where Patients Live: Lessons from a Hybrid Community-Academic Cancer Center
By Swathi Namburi, MD
Dr. Swathi Namburi discusses how hybrid community-academic cancer centers can expand CAR-T access through clinical trials, telehealth, hub-and-spoke care models, and community-based delivery.
Building CAR-T Access Where Patients Live: Lessons from a Hybrid Community-Academic Cancer Center
By Swathi Namburi, MD
Dr. Swathi Namburi discusses how hybrid community-academic cancer centers can expand CAR-T access through clinical trials, telehealth, hub-and-spoke care models, and community-based delivery.
Building CAR-T Access Where Patients Live: Lessons from a Hybrid Community-Academic Cancer Center
By Swathi Namburi, MD
Dr. Swathi Namburi discusses how hybrid community-academic cancer centers can expand CAR-T access through clinical trials, telehealth, hub-and-spoke care models, and community-based delivery.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.